Skip to main content
impaact logo Return to homepage
  • Contact
    • Directory
  • About
    • Mission
    • Network Structure
      • Leadership
    • Areas of Research
      • Cure & Immunotherapy
      • Brain & Mental Health
      • Therapeutics
      • Tuberculosis
      • Social Behavioral Scientific Core (SBSC)
    • Early Career Investigator Program
    • Staff Spotlights
    • Funding Acknowledgements
    • Network Sites
      • Study Site Map
  • Studies
    • Research and Study Opportunities
    • Submit a Research Proposal
    • IMPAACT Study Snapshots
  • Community Engagement
    • ICAB Leadership Group
    • IMPAACT Community Advisory Board (ICAB)
    • Operations Center Staff
    • Resources
      • Acronyms
    • Site Community Advisory Boards
    • Community Meetings and Webinars
  • News & Events
    • Events and Conferences
    • IMPAACT Annual Meeting
    • Newsletters
    • Past Conference Presentations
    • Spotlight Series
  • Resources
    • COVID-19 Resources
    • HIV/AIDS Network Coordination (HANC)
    • Lab Center
      • Laboratory Committees
      • Laboratory Guidance Documents
      • Laboratory Resources for Quality Management
      • MiLab Resources
      • Specimen Repository
    • Manual of Procedures
    • Media Release Form
    • Network Logos & Templates
    • Regulatory Resources
    • Training Opportunities
    • NIH Updates
  • Publications
    • Abstracts
    • Manuscripts
  • Enter a search term.
Back to Directory

Katherine Luzuriaga

Email

katherine.luzuriaga@umassmed.edu

Institution

Division of Pediatric Immunology, Infectious Diseases, and Rheumatology

Title

Professor and Chief
Request an Update

Affiliated Studies

P1007: Phase I Salvage Therapy

DAIDS Number

10315

Research Area

Other

Study Status

Concluded

P1017: PEG-Intron in HIV+Children

DAIDS Number

10317

Research Area

Other

Study Status

Concluded

P1030: Lopinavir/Ritonavir in HIV-1 Infected Infants

DAIDS Number

10041

Research Area

Other

Study Status

Concluded

P1051: Pharmacokinetic Study of Tipranavir with Ritonavir in HIV-infected Patients.

DAIDS Number

10109

Research Area

Other

Study Status

Concluded

P1059: Phase I Trial of Recombinant Vaccines in HIV+ Young Adults

DAIDS Number

10051

Research Area

Other

Study Status

Concluded
Show All
IMPAACT logo Return to homepage

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.

Stay connected with the IMPAACT Network

Follow IMPAACT

Sign up for our newsletter

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Sitemap Privacy Notice

© 2020 IMPAACT Network